Skip to main content
. Author manuscript; available in PMC: 2024 Feb 1.
Published in final edited form as: Clin Nutr. 2023 Jan 11;42(2):235–243. doi: 10.1016/j.clnu.2023.01.009

Table 4.

Observed and Bayesian posterior means, 95% credible intervals and posterior probabilities of a dose effect for early preterm birth rate by quartile baseline DHA status and adherence (postpartum RBC-PL-DHA ≥5.5%) with the high dose. Posterior means and Bayesian 95% credible intervals and posterior probabilities of a dose effect.

Observed early preterm birth <34 weeks, n/N (%) Posterior mean% of EPTB (95% Bayesian credible interval)a Bayesian posterior probabilities
200mg 1000- mg 1000+ mg 200mg 1000- mg 1000+ mg 1000+ mg better than 200 mg 1000+ mg better 1000- mg 1000- mg better than 200 mg
DHA Enrollment (%)
 Quartile 1 (<5.1] 5/112 (4.5) 3/63 (4.8) 2/79 (2.5) 3.4 (1.2,8.0) 3.1 (1.1,7.7) 1.3 (0.4,3.6) 0.92 0.91 0.51
 Quartile 2 (5.1–6.2] 6/132 (4.6) 0/29 (0.0) 0/97 (0.0) 3.5 (1.5,7.7) 2.7 (0.0,6.4) 1.1 (0.0,2.4) 0.97 0.85 0.63
 Quartile 3 (6.2–7.4] 1/110 (0.9) 1/22 (4.5) 2/116 (1.7) 1.3 (0.0,3.8) 3.0 (0.6,8.3) 1.3 (0.4,2.8) 0.50 0.89 0.16
 Quartile 4 (>7.4) 0/136 (0.0) 0/10 (0.0) 1/122 (0.8) 0.6 (0.0,3.3) 2.9 (0.0,7.2) 1.1 (0.2, 2.6) 0.34 0.86 0.12
a

Bayesian hierarchical model was fitted using the approach in Berry and Berry,8 except mu~N(−3.1,10^2). This approach avoids false discoveries in subgroups (quartiles). We burned-in 10,000 draws and used 40,000 draws for inference. High adherence, 1000+ mg, postpartum RBC-PL-DHA ≥ 5.5%; low adherence, 1000- mg, postpartum RBC-PL-DHA <5.5%.